
Image not found or type unknown


Empresa de fabricação de produtos farmacêuticos com 40 anos de existência

Image not found or type unknown



PRINTED ON: *October 29, 2026, 9:56 PM (EST)* **PUBLISHED ON:** *February 10, 2022, 5:01 AM (EST)* **UPDATED ON:** *October 29, 2026, 8:56 PM (EST)*

MERGERSCORP



Empresa de fabricação de produtos farmacêuticos com 40 anos de existência

A empresa foi fundada no distrito de Punjab, na Índia, em 1982, com o objetivo de fabricar ingredientes farmacêuticos ativos.

A empresa é uma empresa de fabricação de ingredientes farmacêuticos ativos (API) que fabrica as matérias-primas para várias empresas líderes do setor farmacêutico, que usam esses produtos para fabricar medicamentos.

Eles fornecem produtos para empresas como Pfizer, Abbott, Cipla, Glenmark, Macleods, Aristo, etc.

As ofertas da empresa variam de antibióticos, vitaminas, anticoagulantes a produtos oftálmicos. A empresa também é auditada por várias organizações, como ISO, ZED e GMP, por órgãos reguladores na Índia e no exterior.

Pesquisa

A empresa está trabalhando em uma tecnologia patenteada para uma proteína recombinante que funciona em uma nova terapia direcionada e também garante a ausência de efeitos colaterais. Atualmente, as operações se concentram em moléculas novas de alta qualidade.

Estudos

Atualmente, a empresa está realizando estudos experimentais sobre terapias de rejuvenescimento com células-tronco, que também prometem um futuro de medicamentos sem efeitos colaterais.

Biotecnologia

A empresa está envolvida na realização de atividades significativas de pesquisa biotecnológica na área de proteínas terapêuticas humanas direcionadas. Seu trabalho de pesquisa atual se concentra na criação de um novo medicamento que, ao mesmo tempo em que cura pacientes com asma e alergia, também pode atuar na mastocitose e na leucemia basofílica.

Equipe

A equipe é composta por 100 pessoas esclarecidas, químicos, farmacêuticos, biotecnólogos, controladores de qualidade, especialistas em P&D e pessoal de armazenamento.

Mercado: 65% Índia / 35% Resto do mundo / Europa

Produtos: 25 OEM Products / Matéria-prima para ingredientes ativos farmacêuticos

Mais vendidos: Antibióticos

Normas: ISO9001, normas da UE (sem FDA)

Taxa de crescimento: 20%+ / ano

Tamanho: mais de 100 funcionários

TARGET PRICE
$40,000,000

GROSS REVENUE
$25,000,000

EBITDA
$3,000,000

BUSINESS TYPE
Farmacêutica

ESTABLISHED
1989

SUPPORT & TRAINING
12 meses

REASON FOR SELLING
Aposentadoria

COUNTRY
Índia

BUSINESS ID
L#20210013


MERGERSCORP M&A INTERNATIONAL IS A GLOBAL BRAND OPERATED BY MERGERSUS INC.A US CORPORATION WITH REGISTERED OFFICE
AT 40TH WALL STREET, SUITE #2725, NEW YORK, NEW YORK 10005, UNITED STATES OF AMERICA.

Gerência: Histórico do engenheiro químico

Financeiro: Receita de US$ 25 milhões / EBITDA de US$ 3 milhões

Clientes:

Image not found or type unknown



MERGERSCORP M&A INTERNATIONAL IS A GLOBAL BRAND OPERATED BY MERGERSUS INC.A US CORPORATION WITH REGISTERED OFFICE AT 40TH WALL STREET, SUITE #2725, NEW YORK, NEW YORK 10005, UNITED STATES OF AMERICA.

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website https://www.mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM